Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Non Operating Income (2020 - 2025)

Xeris Biopharma Holdings' Non Operating Income history spans 6 years, with the latest figure at -$5.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 16.2% year-over-year to -$5.7 million, compared with a TTM value of -$24.3 million through Dec 2025, down 3.77%, and an annual FY2025 reading of -$24.3 million, down 3.77% over the prior year.
  • Non Operating Income for Q4 2025 was -$5.7 million at Xeris Biopharma Holdings, up from -$6.1 million in the prior quarter.
  • The five-year high for Non Operating Income was $1.9 million in Q4 2022, with the low at -$7.6 million in Q3 2023.
  • Average Non Operating Income over 5 years is -$4.5 million, with a median of -$4.8 million recorded in 2022.
  • Biggest YoY gain for Non Operating Income was 175.51% in 2022; the steepest drop was 340.28% in 2022.
  • Tracing XERS's Non Operating Income over 5 years: stood at -$2.5 million in 2021, then soared by 175.51% to $1.9 million in 2022, then tumbled by 299.0% to -$3.8 million in 2023, then plummeted by 79.45% to -$6.8 million in 2024, then increased by 16.2% to -$5.7 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Non Operating Income are -$5.7 million (Q4 2025), -$6.1 million (Q3 2025), and -$6.4 million (Q2 2025).